How do anti-VEGF injections help slow wet AMD progression? 

Anti-vascular endothelial growth factor (anti-VEGF) injections are the primary medical intervention used in the United Kingdom to manage and slow the progression of “wet” age related macular degeneration. In wet AMD, the body incorrectly produces high levels of a protein called VEGF, which triggers the growth of fragile, abnormal blood vessels underneath the macula. These vessels are prone to leaking fluid and blood, which causes the central vision to become distorted or blurred. Anti-VEGF medications work by physically blocking this protein, which effectively “turns off” the signal for new vessel growth and encourages existing leaky vessels to dry up. In the UK, this treatment has revolutionised eye care, with clinical data showing that up to 90% of treated patients experience a stabilisation of their vision. 

What We’ll Discuss in This Article 

• The biological mechanism of how anti-VEGF drugs block protein signals. 

• The physical effect of injections on fluid leakage and macular swelling. 

• Common anti-VEGF medications used in the UK, including biosimilars. 

• The “loading phase” and long-term maintenance schedules. 

• How injections prevent the formation of permanent retinal scars. 

• Clinical success rates and what “stabilisation” means for the patient. 

The biological mechanism: Blocking the VEGF protein 

To understand how these injections work, it is helpful to think of VEGF as a “growth signal.” In a healthy eye, small amounts of VEGF help maintain blood vessels. However, in wet AMD, the eye produces an excess of this signal. Anti-VEGF medications are “monoclonal antibodies” or “fusion proteins” that are specially engineered to seek out and bind to the VEGF molecules in the eye. 

Once the medication is injected into the vitreous (the jelly inside the eye), it acts like a sponge, soaking up the excess VEGF protein. By binding to the protein, the medication prevents it from reaching the receptors on the blood vessels. Without this signal, the abnormal blood vessels stop growing and, importantly, their walls become less “leaky.” This biological blockade is the most direct way to stop the underlying cause of wet AMD progression. You can find more technical details on how anti-VEGF drugs work on the NHS website. 

Drying out the macula and reducing swelling 

The most immediate physical benefit of an anti-VEGF injection is the reduction of macular oedema (swelling). When abnormal vessels leak fluid into the layers of the retina, it causes the macula to thicken and lift away from its normal position. This is what creates the “wavy lines” and “blurring” that patients experience. 

As the anti-VEGF medication begins to work, the “leaks” are sealed. The body’s natural drainage systems can then begin to clear away the trapped fluid. As the macula “dries out” and returns to its normal, flat position, the light sensitive cells can once again capture clear images. This is why many patients in the UK notice an improvement in their vision or a reduction in distortion within a few weeks of their first few treatments. The Macular Society provides visual aids to help patients understand this “drying” process. 

Preventing permanent retinal scarring 

The most critical goal of anti-VEGF therapy is to prevent the final stage of wet AMD, which is the formation of a disciform scar. If fluid and blood are left under the macula for a long period, the delicate retinal tissue is eventually replaced by tough scar tissue. Once a scar has formed, the central vision is permanently lost, and injections can no longer restore it. 

By intervening early with injections, UK ophthalmologists aim to “freeze” the disease in its active state before scarring occurs. Even if the injections do not fully restore “perfect” vision, they are successful if they prevent the transition to permanent scarring. This is why the “14-day rule” in the UK is so strictly followed: the faster the leakage is stopped, the less likely it is that a permanent scar will develop. Clinical standards for preventing retinal damage are set by NICE. 

Common medications and the rise of biosimilars 

In the United Kingdom, several anti-VEGF medications are approved for use. The choice of drug often depends on local clinical pathways and the patient’s specific response. 

• Aflibercept (Eylea): A common first choice that is very effective at binding multiple types of growth factors. 

• Ranibizumab (Lucentis): A well-established drug with a long history of safety and effectiveness. 

• Faricimab (Vabysmo): A newer “dual-action” drug that blocks two different proteins (VEGF and Ang-2), which can help the treatment last longer. 

• Biosimilars (e.g., Ongavia): These are newer, lower cost versions of drugs like ranibizumab that have been proven to be just as safe and effective as the original brands. 

In 2026, the NHS continues to increase the use of biosimilar medications to ensure that as many patients as possible can access these sight saving treatments. All of these drugs work on the same basic principle of blocking the growth signals that drive wet AMD. 

Anti-VEGF Treatment Comparison 

Feature	Initial Loading Phase	Maintenance Phase (Stable)
Frequency	3 to 4 injections (4 weeks apart)	8 to 16 weeks apart
Primary Goal	Stop active leakage/bleeding	Prevent fluid from returning
Monitoring	OCT scan at every visit	OCT scan at every visit
Success Rate	90% achieve stabilisation	Long-term sight preservation
Procedure Time	20 to 30 seconds (Injection only)	20 to 30 seconds (Injection only)

The loading phase and the “Treat and Extend” pathway 

Anti-VEGF treatment is a long-term commitment. In the UK, almost all patients begin with a “loading phase” of three or four monthly injections. This ensures that the concentration of the medication in the eye is high enough to completely shut down the abnormal vessels. After this, most clinics move to a “Treat and Extend” regimen. 

In this pathway, the specialist gradually increases the time between injections as long as the macula remains “dry” on an OCT scan. If your eye stays dry for 8 weeks, the next gap might be 10 weeks. If the fluid returns, the gap is shortened again. This personalised approach ensures that each patient gets just enough medication to keep their AMD in check, reducing the overall “treatment burden” while still offering maximum protection for the macula. 

Conclusion 

Anti-VEGF injections help slow wet AMD progression by biologically blocking the protein signals that cause abnormal blood vessel growth and leakage. By drying out the macula and preventing the formation of permanent scars, these treatments allow many patients in the UK to maintain their central vision and independence for many years. While the treatment is long term, its high success rate in stabilising the condition makes it the cornerstone of modern retinal care. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot 

This article provides a medically accurate explanation of the role of anti-VEGF injections in slowing wet AMD progression. The content was prepared by the Medical Content Team and reviewed by Dr. Rebecca Fernandez, a UK trained physician with experience in internal medicine and acute care. All information presented is strictly aligned with the clinical standards and “Treat and Extend” protocols established by the NHS and the National Institute for Health and Care Excellence (NICE) for 2026.